I believe that shares in Ashmore (LSE: ASHM) are due for a bounce as conditions in key emerging market improve. The business has suffered from weakened client activity over the past year, but with cyclical problems now abating and the financial ...
GlaxoSmithKline plc logo GlaxoSmithKline plc (LON:GSK)'s stock had its “underperform” rating restated by research analysts at Credit Suisse in a report released on Thursday, Market Beat Ratings reports.
The last year has been hugely disappointing for investors in BP (LSE: BP) (NYSE: BP.US) and GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US), with the share prices of the two companies both falling by 11%. And, while neither of them are the biggest stock in ...
2015 is shaping up to be a pretty terrible year for GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US). Year to date, the company's shares have hardly budged while the rest of the FTSE All World Pharma & Biotech sector has risen by 10%.
A newly floated US biotech company has achieved a valuation of $2.2bn. Good for them, you say? You might not think that if you're a GlaxoSmithKline (LSE: GSK) shareholder and you learn who Axovant got its sole product from - and what it paid!
In this investing video, Champion Shares PRO portfolio manager Nathan Parmelee discusses GlaxoSmithKline's (LSE: GSK) decision to make its dividend payout the top priority and how that might lower its long-term growth potential.
biotech Tony Daltorio: Jim O'Neill, the former chief economist at Goldman Sachs, is best known for coining the BRIC acronym, which stands for the emerging market countries Brazil, Russia, India and China.